Table 1.

Summary of available clinical trial data

Trial Name/NCT No.	Study Design	N, Population	eGFR Cutoff	Remdesivir Duration, d	Outcomes
NIAID ACTT-1 study	Double-blind, placebo-controlled RCT	1063 hospitalized adult patients, international	30	10	Interim analysis: median time to recovery 11 versus 15 d; P<0.001; mortality 8% versus 11.6%; P=0.06
NCT04292899	Randomized, open-label trial	197 adults with severe COVID-19, international	50	5 versus 10	70% clinical recovery and 59% clinical recovery by 14 d in 5- and 10-d groups
Compassionate use program	Open label, multicenter, nonrandomized	>1200 adults, 76 children with COVID-19, international	30	10	Report of 61 treated patients, 8 lost to follow-up; 36 of 53 improved at a median follow-up of 18 d2
NCT04257656	Double-blind, placebo-controlled RCT	237 adults with severe COVID-19, China	30	10	No difference in time to clinical improvement; equivalent number of renal AEs in placebo and remdesivir arms3

In all cases, remdesivir dosing begins with a 200-mg intravenous loading dose followed by 100 mg intravenously daily. Currently available clinical trial data supporting remdesivir use are shown. NCT, national clinical trial; NIAID ACTT-1, National Institute of Allergy and Infectious Diseases Adaptive Covid-19 Treatment Trial; RCT, randomized, controlled trial; AE, adverse event.